Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Jun 6;12(6):e228108.
doi: 10.1136/bcr-2018-228108.

Myoclonic status epilepticus induced by cefepime overdose requiring haemodialysis

Aude Garin  1 , Florent Bavozet  1
Affiliations
Case Reports

Myoclonic status epilepticus induced by cefepime overdose requiring haemodialysis

Aude Garin et al. BMJ Case Rep. .

Abstract

We report a case of cefepime neurotoxicity characterised by myoclonic status epilepticus with coma, in a context of acute renal failure and requiring one discontinuous conventional haemodialysis. Cefepime is a fourth-generation broad-spectrum cephalosporin mainly used to treat hospital-acquired Gram-negative infections. Acute neurotoxicity is an increasingly reported adverse effect which occurs predominantly in patients with renal impairment. Renal replacement therapy has been proposed to treat this condition.

Keywords: dialysis; epilepsy and seizures; healthcare improvement and patient safety; unwanted effects/adverse reactions.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Diffuse arrhythmic paroxysmal abnormalities related to status epilepticus.
Figure 2
Figure 2
Non-reactive isoelectric tracing under thiopental therapy.
See this image and copyright information in PMC

References

    1. Payne LE, Gagnon DJ, Riker RR, et al. Cefepime-induced neurotoxicity: a systematic review. Crit Care 2017;21:276 10.1186/s13054-017-1856-1 - DOI - PMC - PubMed
    1. Grill MF, Maganti R. Cephalosporin-induced neurotoxicity: clinical manifestations, potential pathogenic mechanisms, and the role of electroencephalographic monitoring. Ann Pharmacother 2008;42:1843–50. 10.1345/aph.1L307 - DOI - PubMed
    1. Lam S, Gomolin IH. Cefepime neurotoxicity: case report, pharmacokinetic considerations, and literature review. Pharmacotherapy 2006;26:1169–74:1169–74. 10.1592/phco.26.8.1169 - DOI - PubMed
    1. Dakdouki GK, Al-Awar GN. Cefepime-induced encephalopathy. Int J Infect Dis 2004;8:59–61. 10.1016/j.ijid.2003.09.003 - DOI - PubMed
    1. Cefepime [package insert]. Bristol-Myers Squibb Company, Princeton, NJ. 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050679s036lbl.pdf (accessed Nov 2016).

Publication types

MeSH terms